Почетна › Akutna mijeloidna leukemija › Alabama
Kliničke studije za Akutna mijeloidna leukemija u državi Alabama
21 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Alabama.
Gradovi u državi Alabama
Zvanični tekst studije (na engleskom)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
Тражи се учесникОпсервациона студија
Узраст од 12 до 80 · Оба пола · Ажурирано 6. 11. 2026. · NCT07145411A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- University of Alabama O'Neal Cancer Center, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 23. 10. 2026. · NCT07012044A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
Тражи се учесникФаза 3
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- University of Alabama - Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06824168Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
Тражи се учесникФаза 3
Узраст од 1 до 25 · Оба пола · Ажурирано 4. 9. 2026. · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Alabama Birmingham, Birmingham
Тражи се учесникФаза 2/3
Узраст од 18 до 80 · Оба пола · Ажурирано 5. 8. 2026. · NCT06788756A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Тражи се учесник
Узраст 60 и старији · Оба пола · Ажурирано 6. 7. 2026. · NCT06697600A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Alabama at Birmingham, Birmingham
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 4. 3. 2026. · NCT07044544Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- The Kirklin Clinic of UAB Hospital, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2025. · NCT03850574Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- University of Alabama - Birmingham, Birmingham
Тражи се учесникЗдраве особе су добродошле
Узраст од 18 до 120 · Оба пола · Ажурирано 25. 7. 2025. · NCT05237258Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 11. 2024. · NCT06034275Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.